ClinicalTrials.gg
CompletedNCT04683406Updated Jun 27, 2023

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

A Phase 3 interventional study of ZSP1273 600 mg and Placebo to Oseltamivir in Influenza A, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 76 sites in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
52nd of 157
750 · median 360
Started
2020
with 7 others
Phase 3
46 of 173
9 open now
Registered
93rd of 173
by date
Lead sponsor
5 of 173
Guangdong Raynovent Biotech Co., Ltd

Among the 173 studies in Influenza, Human with a site in China, this one is the 52nd largest by enrollment of the 157 interventional ones that give a count, is one of 8 that started in 2020, is one of 46 in phase 3, and was the 93rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.

03

Conditions studied

  • Influenza A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are able to understand the study and comply with all study procedures, and willing to provide written /assent prior to the predose examinations appropriately.
  2. Male or female patient s aged ≥ 18 to ≤ 64 years at the time of signing the informed consent/assent form
  3. Patients with a diagnosis of influenza virus infection confirmed by all of the following

    • Positive Rapid Antigen Test (RAT) with throat swabs;and
    • Fever ≥ 38ºC (axillary) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken;and
    • At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater I. Headache II. Feverishness or chills III. Muscle or joint pain IV. Fatigue
    • At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater I. Cough II. Sore throat III. Nasal congestion
  4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either

    • Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
    • Time when the patient experiences at least one general or respiratory symptom
  5. Women of (WOCBP) who agree to use a highly effective method of for 3 months after the first dose of ZSP1273 or oseltamivir

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment
  2. Patients aged ≥ 18 years with known allergy to oseltamivir (Tamiflu) or ZSP1273
  3. Patients unable to swallow tablets or capsules or any medical history in gastrointestinal that interferes with the absorption of drugs
  4. Patients who have received antiviral medication including peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 7 days prior to the predose examinations
  5. Patients who have received Chinese patent medicine or herbal medicine with antiviral effect within 7 days prior to the predose examinations
  6. Patients who have received Anti-influenzal prescription within 7 days prior to the predose examinations
  7. Subject who produces purulent sputum or has suppurative tonsillitis.
  8. White blood cells(WBC)>10.0×109/L at screening.
  9. Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.
  10. Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.
  11. Patients with severe or uncontrollable underlying diseases:blood disorders,severe (COPD),liver disorders( or AST≥3 ,total ≥1.5 ULN),kidney disorders(serum creatinine>177μmol/L or 2mg/dL),chronic congestive heart failure( III-IV),mental disorders
  12. Immunodeficiency,including malignant tumor,organ or marrow transplant, [HIV] infection,or patients receiving therapy 3 months prior to enrollment.
  13. Concomitant therapy with aspirin or salicylic acid.
  14. Patients weighing \< 40 kg or morbid obesity( [BMI]≥30kg/m2)
  15. Known history of alcohol abuse or drug abuse
  16. Pregnancy or breastfeeding at screening and during the study.All female subjects of must have a negative urine pregnancy test at screening and during the trial.
  17. Have received any other products within 3 months prior to dosing.
  18. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
750 participants (actual)

Study arms

  • Experimental
    ZSP1273 600 mg + Oseltamivir Placebo BID

    Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days

    Drug: ZSP1273 600 mg · Drug: Placebo to Oseltamivir

  • Active comparator
    Oseltamivir 75mg + ZSP1273 Placebo

    Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days

    Drug: Oseltamivir(oral) · Drug: Placebo to ZSP1273

  • Placebo comparator
    Placebo Comparator

    Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days

    Drug: Placebo to Oseltamivir · Drug: Placebo to ZSP1273

Interventions

  • 3 X 200-mg tablet taken orally

  • DrugPlacebo to Oseltamivir

    Placebo capsules matching oseltamivir2 X 75-mg

  • 2 X 75-mg tablet taken orally

  • DrugPlacebo to ZSP1273

    Placebo capsules matching ZSP1273 600 mg

06

What researchers measure

Primary outcomes

  1. Time to Alleviation of Symptoms in Participants Randomized to ZSP1273 or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point

    Time frame: Up to 14 days after first dose

  2. Time to Alleviation of Symptoms in Participants Randomized to ZSP1273 or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point

    Time frame: Up to 14 days after first dose

Secondary outcomes

  1. Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Virus titer was quantified from nasopharyngeal swabs by tissue culture methods.

    Time frame: Days 2, 4, 6

  2. Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Virus titer was quantified from nasopharyngeal swabs by tissue culture methods.

    Time frame: Days 2, 4, 6

  3. Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs.

    Time frame: Days 2, 4, 6

  4. Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs.

    Time frame: Days 2, 4, 6

  5. Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Virus titer was quantified from nasopharyngeal swabs.

    Time frame: Days 2, 4, 6

  6. Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Virus titer was quantified from nasopharyngeal swabs.

    Time frame: Days 2, 4, 6

  7. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Nasopharyngeal swabs were obtained for viral quantitation.

    Time frame: Days 2, 4, 6

  8. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Nasopharyngeal swabs were obtained for viral quantitation.

    Time frame: Days 2, 4, 6

  9. Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to ZSP1273 or Placebo

    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 5. AUC was calculated using the trapezoidal method

    Time frame: Up to 6 days after first dose

  10. Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to ZSP1273 or Oseltamivir

    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 5. AUC was calculated using the trapezoidal method

    Time frame: Up to 6 days after first dose

  11. Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to ZSP-1273 or Placebo

    Time frame: Up to 6 days after first dose

  12. Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to ZSP1273 or Oseltamivir

    Time frame: Up to 6 days after first dose

  13. Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to ZSP1273 or Placebo

    Time frame: Up to 6 days after first dose

  14. Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to ZSP1273 or Oseltamivir

    Time frame: Up to 6 days after first dose

  15. Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1)

    Time frame: Up to 14 days after first dose

  16. Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1)

    Time frame: Up to 14 days after first dose

  17. Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to ZSP1273 or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Up to 14 days after first dose

  18. Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to ZSP1273 or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Up to 14 days after first dose

  19. Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to ZSP1273 or Placebo

    * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours * Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point

    Time frame: Up to 14 days after first dose

  20. Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to ZSP1273 or Oseltamivir

    * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours * Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point

    Time frame: Up to 14 days after first dose

  21. Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms) * The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant at each time point

    Time frame: Up to 14 days after first dose

  22. Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms) * The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant at each time point

    Time frame: Up to 14 days after first dose

  23. Time to Resolution of Fever in Participants Randomized to ZSP1273 or Placebo

    * Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours * Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point

    Time frame: Up to 14 days after first dose

  24. Time to Resolution of Fever in Participants Randomized to ZSP1273 or Oseltamivir

    * Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours * Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point

    Time frame: Up to 14 days after first dose

  25. Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to ZSP1273 or Placebo

    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment

    Time frame: Up to 14 days after first dose

  26. Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir

    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment

    Time frame: Up to 14 days after first dose

  27. Time to Alleviation of Individual Symptoms in Participants Randomized to ZSP1273 or Placebo

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

    Time frame: Up to 14 days after first dose

  28. Time to Alleviation of Individual Symptoms in Participants Randomized to ZSP1273 or Oseltamivir

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

    Time frame: Up to 14 days after first dose

  29. Time to Return to Preinfluenza Health Status in Participants Randomized to ZSP1273 or Placebo

    Time frame: Up to 14 days after first dose

  30. Time to Return to Preinfluenza Health Status in Adults Randomized to ZSP1273 or Oseltamivir

    Defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.

    Time frame: Up to 14 days after first dose

  31. Percentage of Participants With Influenza-related Complications in Participants Randomized to ZSP1273 or Placebo

    Defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.

    Time frame: Up to 14 days after first dose

  32. Percentage of Participants With Influenza-related Complications in Participants Randomized to ZSP1273 or Oseltamivir

    Time frame: Up to 14 days after first dose

  33. Change in EQ-5D-5L

    Defined as the change from baseline in the index value and that in EQ VAS score as calculated from the EQ-5D-5L questionnaire.

    Time frame: Up to 14 days after first dose

07

Study locations

76 sites
  • The First Affiliated Hospital of bengbu medical college
    Bengbu, Anhui, China
  • Xuancheng People's Hospital
    Xuancheng, Anhui, China
  • Beijing Chaoyang Hospital,Capital Medical University
    Beijing, Beijing, China
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • People's Hospital of Cuanjiang, Chongqing
    Chongqing, Chongqing, China
  • Third Military Medical University
    Chongqing, Chongqing, China
  • Quanzhou First Hospital
    Quanzhou, Fujian, China
  • Fujian Provincal Hospital
    Xiamen, Fujian, China
  • Xiamen Hospital of T.C.M
    Xiamen, Fujian, China
  • Xiamen Zhongshan Hospital
    Xiamen, Fujian, China
  • Dongguan People's Hospital
    Dongguan, Guangdong, China
  • Foshan First People's Hospital
    Foshan, Guangdong, China
  • Shunde University of Southern Medical University
    Foshan, Guangdong, China
  • Guangdong Province Traditional Chinese Medical Hospital
    Guangzhou, Guangdong, China
  • Nanfang Hospital
    Guangzhou, Guangdong, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital Of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Huizhou Central People's Hospital
    Huizhou, Guangdong, China
  • Jieyang People's Hospital
    Jieyang, Guangdong, China
  • Qingyuan People's Hospital
    Qingyuan, Guangdong, China
  • Shantou Central Hospital
    Shantou, Guangdong, China
  • Yuebei People's Hospital
    Shaoguan, Guangdong, China
  • Shenzhen Luohu Hospital Group Luohu People's Hospital
    Shenzhen, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • Songgang People's Hospital
    Shenzhen, Guangdong, China
  • Nanning First People's Hospital
    Nanning, Guangxi, China
  • Guizhou Provicial People's Hospital
    Guiyang, Guizhou, China
  • Affiliated Hospital Zunyi Medical College
    Zunyi, Guizhou, China
  • First Hospital of Qinhuangdao
    Qinhuangdao, Hebei, China
  • Huaihe Hospital of Henan University
    Huaihe, Henan, China
  • Luoyang Central Hospital Affiliated To Zhengzhou University
    Luoyang, Henan, China
  • Nanyang Central Hospital
    Nanyang, Henan, China
  • Nanyang First People's Hospital
    Nanyang, Henan, China
  • The Second People's hospital of Nanyang
    Nanyang, Henan, China
  • The Third Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan, China
  • The Third Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan, China
  • Henan Provicial People's Hospital
    Zhengzhou, Henan, China
  • Zhengzhou Central Hospital
    Zhengzhou, Henan, China
  • Zhengzhou Sixth Hospital
    Zhengzhou, Henan, China
  • Yiyang Central hospital
    Yiyang, Hunan, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • Nanjing Jiangning Hospital
    Nanjing, Jiangsu, China
  • Sir run run Hospital Nanjing Medical University
    Nanjing, Jiangsu, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi, China
  • Jiujiang University Affiliated Hospital
    Jiujiang, Jiangxi, China
  • First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi, China
  • The Third Hospital Of Nanchang
    Nanchang, Jiangxi, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • Shangyao People's Hospital
    Shangyao, Jiangxi, China
  • The First Hospital Of Jilin University
    Changchun, Jilin, China
  • General Hospital of Liaohe Oilfield
    Panjin, Liaoning, China
  • Shenyang Central Hospital Affiliated To Shenyang medical college
    Shenyang, Liaoning, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong, China
  • Heze Municipal Hospital
    Heze, Shandong, China
  • Jinan Central Hospital
    Jinan, Shandong, China
  • Liaocheng People's Hospital
    Liaocheng, Shandong, China
  • Linyi People's Hospital
    Linyi, Shandong, China
  • Shandong Energy Zaozhuang Mining
    Zaozhuang, Shandong, China
  • PKUCare luzhong Hospital
    Zibo, Shandong, China
  • Shanghai East Hospital
    Shanghai, Shanghai, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Chengdu Xinhua Hospital
    Chengdu, Sichuan, China
  • General Hospital of Western Theater of PLA
    Chengdu, Sichuan, China
  • Sichuan Provicial People's Hospital
    Chengdu, Sichuan, China
  • The Third People's Hospital of Wuhou, Chengdu
    Chengdu, Sichuan, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Dazhou Central Hospital
    Dazhou, Sichuan, China
  • Affiliated Hospital of North Sichuan College
    Nanchong, Sichuan, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • The first People hospital of Yunnan Province
    Kunming, Yunnan, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Ruian People's Hospital
    Ruian, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Apr 2023, 27 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 27 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2020
First posted
Dec 24, 2020
StartActual
Dec 28, 2020
Primary completionActual
Apr 1, 2023
CompletionActual
May 16, 2023
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04683406
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Dec 28, 2020
Primary completion
Apr 1, 2023
Completion
May 16, 2023
Last update
Jun 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion